REFERENCES
- Greenlee RT, Murray T, Bolden S et al. Cancer Statistics, 2000.CA Cancer J Clin 50: 7-33, 2000.
- Burris HA, Moore MJ, Andersen J et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreatic cancer: a ran-domized trial. J Clin Oncol 1997; 15: 2403-2413.
- Storniolo AM, Enas NH, Brown CA, et al. An investiga-tional new drug treatment program for patients with gemc-itabine. Results for over 3000 patients with pancreatic carci-noma. Cancer 1999; 85: 1261–1268.
- Aigner KR, Muller H, Bassermann R et al. Intra-arterial chemotherapy with MMC, CDDP and 5FU for non resectable pancreatic cancer: a phase II study. Reg Cancer Treat 1990; 3: 1–6.
- Link KH, Gansauge F, Pillash J et al. Regional treat-ment of advanced nonresectable and of resected pancreatic cancer via celiac axis infusion. Dig Surg 1994; 11: 414–419.
- Muchmore JH. Treatment of advanced pancreatic can-cer with regional chemotherapy plus hemofilatration. Semin Surg Oncol 1995; 11: 1–14.
- Cantore M, Fiorentini G, Bassi C, et al. Intra-arterial chemotherapy for stage III/IV pancreatic cancer. Dig Surg 1997; 14: 113–118.
- Cantore M, Pederzoli P, Fiorentini G et al. Intra-arterial chemotherapy for unresectable pancreatic cancer. Ann Oncol 2000; 11: 569–573.
- Goldstein II, Galski H, Fojo A, et al. Expression of multidrug resistance gene in human cancers. J Nat Cancer Inst 1989; 81: 116–124.
- Miller DW, Fontain M, Kolar C et al. The expression of mutidrug resistance-associated protein (MRP) in pancreatic adenocarcinoma cell lines. Cancer Lett 1996; 107: 301–306.
- Verovski VN, Van den Berge DL, Delvaeye MM et al. Low-level doxorubicin resistance in P-glycoprotein-negative human pancreatic tumor PSN1/ADR cells implicates a brefeldin A-sensitive mechanism of drug extrusion. Br J Cancer 1996; 73: 596–602.
- Kartner N, Riorden JR, Ling V. Cell surface P-glyco-protein associated with multidrug resistance in mammalian cell lines. Science 1983; 221: 1285–8.
- Goldstein II, Galski H, Fojo A et al. Expression of the multidrug resistance gene product P-glycoprotein in human cancer. J Natl Cancer Inst 1989; 81: 116.
- Thiebaut F, Tsuruo T, Hamada H et al. Cellular local-ization of the multidrug resistance gene product P-glycoprotein in normal human tissue. Proc Natl Acad Sci USA 1987; 84: 7735–7738.
- Almoquera C, Shibata D, Forrester K et al. Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell 1988; 53: 549–554.
- Scarpa A, CapeIli P, Mukai K et al. Pancreatic adeno-carcinomas frequently show p53 gene mutations. Am J Pathol 1993; 142: 1534–1543.
- Chin KV, Ueda K, Pastan I, et al. Modulation of the activity of the promoter of the human MDR1 gene by ras and p53. Science 1992; 255: 459–462.
- Morrow CS, Cowan KH. Glutathione S-transferases and drug resistance. Cancer Cells 1990; 2: 15–22.
- Link KH, Kindler D, Hummel M, et al. Dose response treatment studies with two pancreatic carcinoma cell lines in vitro (abstract). Digestion 1992; 52:102.
- Donatini B, Rougier P. Anatomical basis for pancreatic locoregional chemotherapy. Reg Cancer Treat 1992; 4: 272–276.
- Griffin JF, Smalley SR, Jewell W. Patterns of failure after curative resection of pancreatic carcinoma. Cancer 1990; 66: 56–61.
- Andren-Sandberg A, Westerdhal J, Ihse I. Recurrence after pancreatectomy for pancreatic carcinoma. Digestion 1992; 52: 67.
- Klapdor R, Muller C, Seutter R et al. Improvement of survival by efficacy orientated sequential polychemotherapy of exocrine pancreatic cancer. Anticancer Res 2000; 20: 5201–5208.